10.14.25 -- Manufacturing Interleukin-2 For In Vivo Use: Key Considerations

Improvements include the development of alternative approaches to gene delivery, advances in upstream and downstream processing, analytical methods, and intensified/continuous processing.

There are two primary filling methods for pre-filled syringes. Delve into the pros and cons of each approach, highlighting why barrel filling is generally preferred in the pharmaceutical industry.

Investing in adaptable aseptic manufacturing pays off. Find out how flexible systems, despite higher initial costs, handle complex drugs and changing volumes to boost productivity and quality.

Proactively understanding containment system performance can streamline development and accelerate market delivery. Review comparative data for CZ-based systems and traditional glass or polypropylene options.

Learn more about two unique methods for clinical-scale expansion of gamma delta T cells, which are well suited for a wide variety of treatments due to their reduced risk of graft-versus-host disease.

Grasp the insights about a scalable, microcarrier-based 3D culture process for expanding hiPSCs to 10L, yielding over 10 billion cells while maintaining quality.

Next Generation Sequencing (NGS) offers a sensitive, high-throughput solution for detecting adventitious viral agents (AVAs), improving biopharmaceutical safety and accelerating regulatory-compliant product development.

Perfusion cell culture technology supports high cell densities and product yields for viral vaccine manufacturing, offering a reliable way to produce high-quality cells at a commercial scale.

Scaling up life-saving gene-edited cell therapies means tackling production inefficiencies. Overcoming the time-consuming and risky cell washing step is crucial for clinical and commercial success.

Uncover how you can revolutionize your stem cell research with a stable, plant-based growth factor that simplifies culture maintenance and boosts cell health.

Biological components in conditioned media are a consistent problem during downstream processing of EVs. A novel in-process reagent prevents these issues and improves particle recovery 10-fold while maintaining CQAs.

The transition from manual to automated cell processing is vital for therapeutic success. A versatile, single-use system simplifies operations, reduces variability, and ensures product quality throughout manufacturing.

Discover how self-replicating RNA (srRNA) can revolutionize vaccine development with sustained protein expression, lower doses, and fewer side effects to advance next-gen RNA therapeutics.